GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs

Metabolic Brain Disease

Volumn 30, Issue 5, 2015, Pages 1207-1215

  Queiroz, Ana Isabelle G ^a   de Araújo, Maíra Moraes ^a   da Silva Araújo, Tatiane ^a   de Souza, Greicy Coelho ^a   Cavalcante, Lígia Menezes ^a   de Jesus Souza Machado, Michel ^a   de Lucena, David Freitas ^a   Quevedo, João ^b,c   Macêdo, Danielle ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Bipolar disorder; GBR12909; Lithium; Mania; Mice; Valproate

Indexed keywords

GLUTATHIONE; LITHIUM; SODIUM CHLORIDE; VANOXERINE; DOPAMINE UPTAKE INHIBITOR; PIPERAZINE DERIVATIVE; TRANQUILIZER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BIPOLAR MANIA; BRAIN; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; EXPERIMENTAL HYPERACTIVITY; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROPHYLAXIS; RANDOMIZATION; REARING; AFFECT; ANIMAL; BIPOLAR DISORDER; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; TIME FACTOR;

AFFECT; ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; LIPID PEROXIDATION; MALE; MICE; OXIDATIVE STRESS; PIPERAZINES; TIME FACTORS;

EID: 84941186747     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-015-9697-6     Document Type: Article

References (44)

1. Anand A, Barkay G, Dzemidzic M et al (2011) Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord 13:406–413. doi:10.1111/j.1399-5618.2011.00936.x
2. Andersen PH (1987) Biochemical and pharmacological characterization of [3 H]GBR 12935 binding in vitro to rat striatal membranes: labeling of the dopamine uptake complex. J Neurochem 48:1887–1896. doi:10.1111/j.1471-4159.1987.tb05752.x
3. Andreazza AC, Kauer-Sant’anna M, Frey BN et al (2008) Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 111:135–144
4. Andreazza AC, Shao L, Wang J-F, Young LT (2010) Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 67:360–368. doi:10.1001/archgenpsychiatry.2010.22
5. Archer J (1973) Tests for emotionality in rats and mice: a review. Anim Behav 21:205–235
6. Barr AM, Lehmann-Masten V, Paulus M et al (2004) The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology 29:221–228. doi:10.1038/sj.npp.1300343
7. Beaulieu J-M, Sotnikova TD, Yao W-D et al (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 101:5099–5104. doi:10.1073/pnas.0307921101
8. Berk M, Dodd S, Kauer-Sant’anna M et al (2007) Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 41–49. doi:10.1111/j.1600-0447.2007.01058.x
9. Berk M, Kapczinski F, Andreazza AC et al (2011) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35:804–817
10. Brown AM, Chand N (2010) Using vanoxerine type medicant; blocking calcium channel current
11. Cappeliez P, Moore E (1990) Effects of lithium on an amphetamine animal model of bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 14:347–358
12. Cui J, Shao L, Young LT, Wang J-F (2007) Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144:1447–1453. doi:10.1016/j.neuroscience.2006.11.010
13. da-Rosa DD, Valvassori SS, Steckert AV et al (2012) Effects of lithium and valproate on oxidative stress and behavioral changes induced by administration of m-AMPH. Psychiatry Res 198:521–526. doi:10.1016/j.psychres.2012.01.019
14. Davies C, Sanger DJ, Steinberg H et al (1974) Lithium and alpha-methyl-p-tyrosine prevent “manic” activity in rodents. Psychopharmacologia 36:263–274
15. Drevets WC, Price JL, Furey ML (2008) Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 213:93–118. doi:10.1007/s00429-008-0189-x
16. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77
17. Frey BN, Martins MR, Petronilho FC et al (2006a) Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord 8:275–280. doi:10.1111/j.1399-5618.2006.00318.x
18. Frey BN, Valvassori SS, Reus GZ et al (2006b) Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 31:326–332
19. Frey BN, Andreazza AC, Houenou J et al (2013) Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry 47:321–332
20. Goodwin FK, Jamison KR (2007) Manic-depressive illness: bipolar disorders and recurrent depression
21. Goto Y, Grace AA (2005) Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nat Neurosci 8:805–812. doi:10.1038/nn1471
22. Greenwood TA, Schork NJ, Eskin E, Kelsoe JR (2006) Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples. Mol Psychiatry 11:125–133, 115. doi:10.1038/sj.mp.4001764
23. Kuloglu M, Ustundag B, Atmaca M et al (2002) Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20:171–175. doi:10.1002/cbf.940
24. Macêdo DS, Medeiros CD, Cordeiro RC, et al (2012) Effects of alpha-lipoic acid in an animal model of mania induced by D-amphetamine. Bipolar Disord 14:707–718. doi:10.1111/j.1399-5618.2012.01046.x
25. Macedo DS, de Lucena DF, Queiroz AI et al (2013) Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania. Prog Neuro-Psychopharmacol Biol Psychiatry 43:230–237
26. Martinez-Aran A (2004) Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 161:262–270. doi:10.1176/appi.ajp.161.2.262
27. Meiser J, Weindl D, Hiller K (2013) Complexity of dopamine metabolism. Cell Commun Signal 11:34. doi:10.1186/1478-811X-11-34
28. Miyazaki I, Asanuma M (2008) Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama 62:141–150
29. Moretti M, Valvassori SS, Steckert AV et al (2011) Tamoxifen effects on respiratory chain complexes and creatine kinase activities in an animal model of mania. Pharmacol Biochem Behav 98:304–310. doi:10.1016/j.pbb.2011.01.017
30. Morice R (1990) Cognitive inflexibility and pre-frontal dysfunction in schizophrenia and mania. Br J Psychiatry 157:50–54
31. Nascimento C, Kyunghee H, Trevor KL, Andreazza AC (2014) Glutathione-mediated effects of lithium in decreasing protein oxidation induced by mitochondrial complex I dysfunction. doi:10.1007/s00702-014-1318-8
32. NIH (1996) Guide for the care and use of laboratory animals- Institute of Laboratory Animal Research- National Research Council. Natl. Acad. Press
33. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358
34. Pinsonneault JK, Han DD, Burdick KE et al (2011) Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology 36:1644–1655. doi:10.1038/npp.2011.45
35. Raffa M, Barhoumi S, Atig F et al (2012) Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 39:371–375. doi:10.1016/j.pnpbp.2012.07.013
36. Ralph-Williams RJ, Paulus MP, Zhuang X et al (2003) Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry 53:352–359
37. Rao JS, Kellom M, Reese EA, et al (2012) Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J Affect Disord 136:63–71. doi:10.1016/j.jad.2011.08.017
38. Rush CR, Essman WD, Simpson CA, Baker RW (2001) Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol 21:273–286
39. Valvassori SS, Rezin GT, Ferreira CL et al (2010) Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J Psychiatr Res 44:903–909. doi:10.1016/j.jpsychires.2010.02.009
40. Van Enkhuizen J, Geyer MA, Kooistra K, Young JW (2013a) Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice. Int J Neuropsychopharmacol 16:1021–1031. doi:10.1017/S1461145712001198
41. Van Enkhuizen J, Geyer MA, Young JW (2013b) Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania. Psychopharmacology 225:661–674. doi:10.1007/s00213-012-2854-2
42. Young JW, Goey AKL, Minassian A et al (2010) GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology 208:443–454. doi:10.1007/s00213-009-1744-8
43. Young JW, Henry BL, Geyer MA (2011a) Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol 164:1263–1284
44. Young JW, van Enkhuizen J, Winstanley CA, Geyer MA (2011b) Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J Psychopharmacol 25:934–943. doi:10.1177/0269881111400646